AcreBooks -  Sel Edor & Stephen Thor
Acrebooks is a reading company. We create products that improve your digital reading and writing experience. Our initial product is called authorpad. Authorpad simplifies book production and promotion for self-published authors by offering cost-effective and value adding services to self-published author. Production services include editing, eBook formats, and cover design. Promotion services include press releases, social media account management and book listings. Our strategy is to introduce authors to our low cost production services and upsell them to our promotional service which is a monthly recurring product.
www.acrebooks.com

ArgentumCidalElectrics (ACE) - Tom Fuller & Seth Zimmerman
“ACE” has a novel antimicrobial technology, which controls metal ion release to provide the most powerful, “self-cleaning” surface technology in the world. There is an unmet need—that ACE alone can satisfy—for antimicrobial protection on 14 high touch surfaces in hospitals. ACE intends to focus initially on bed rail surfaces, which are touched 2x more than any other surface and hold up to 89% of the pathogens in patient rooms, and to then pursue development of the remaining 13 high touch surfaces.   7 issued (3-U.S., Canada, Mexico, Japan, Singapore) and 9 pending patents (4-U.S., Canada, E.U., India, Israel, Hong Kong).
www.argentumce.com

IVF Cell Technology – Todd Waybright
We provide embryos produced by in vitro fertilization for impregnating infertile dairy cattle. Infertile animals are 3 times more likely to conceive to an IVF embryo than they are to conceive to semen.  No other IVF company provides embryos for use in infertile animals.  Our embryos will be provided in straws similar to those used to inseminate cattle with semen.  We will initially market our embryos to veterinarians that provide service to dairy farms.  After the initial startup phase, we will also market embryos directly to farms.

Leafy - Amin Afzal
We provide a device based on an innovative leaf water content sensor that accurately estimates plant water status. This sensor is employed in an irrigation scheduling system for optimization of water consumption and crop yield. Our goal is to find partners and sell our product directly, through partners, and licensing. Our development will be based on collaboration with Penn State research groups, Ben Franklin, and other resources.

Penergy Solutions - Keppy Arnoldsen & Jen Breimhurst
Our small-farm anaerobic digester provides a unique way for farmers to utilize their manure wastes and an opportunity to pair those with food wastes from the restaurant and food manufacturing sectors for improved input ingredients.  We plan to sell the digesters in single and double 40-ft sections.  An upgraded whole system is offered with our innovative greenhouse structure that includes options for a solar panel, hot water heater, and hydroponics crop production or aquaponics fish production setups.  A license fee will be charged for use of our technology.

The second portion of the business plan is to market the digester tea for sale on the agricultural market place.  We will set up a bottling and production plant for the fertilizer production. Methane gas generated from the digester will be harnessed to heat water for concentrating and treating the fertilizer extract. Food wastes when added exponentially increase the production of methane gas from the digester making this a valuable pairing of waste products. The digester tea will be called Fer-TEA-lizer and we plan to market it through existing organic fertilizer distributors.
www.penergysolutions.weebly.com

Trans-Cell Conversion Technology – Gong Chen & Gangyi Wu
Our goal is to build a leading clinical-oriented biopharmaceutical company based on our proprietary in vivo cell conversion technology for brain repair to treat brain injury and neurodegenerative disorders. Our preclinical studies have demonstrated the proof-of-principle that reactive glial cells induced by injury and disease can be effectively converted into functional neurons to restore the lost brain function. The mission of our company is to advance our innovative technology from preclinical studies to clinical trials to ultimately translate into a clinical therapy.  The core technology on in vivo cell conversion is based on a pending patent originally developed by our founder (Gong Chen) at Penn State University. We are further developing small molecule-based methods for in vivo conversion, which will be filed as a separate patent application. We expect a series of new patent applications to perfect the technology, together with a series of trade secrets of when, where, and how to deliver the viruses or small molecules.